Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization 50% Improvement Relative Risk Case 27% c19hcq.org Rajasingham et al. NCT04328467 HCQ RCT PrEP Favors HCQ Favors control
Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial
Rajasingham et al., medRxiv, doi:10.1101/2020.09.18.20197327, COVID PREP, NCT04328467 (history)
Rajasingham et al., Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial, medRxiv, doi:10.1101/2020.09.18.20197327, COVID PREP, NCT04328467
Sep 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
PrEP RCT showing HR 0.73, p = 0.12. Trial halted after 47% enrollment, p < 0.05 will be reached at ~75% enrollment if similar results continue.
HR 0.66/0.68 for full medication adherence, 0.72/0.74, p = 0.18/0.22 overall (1x/2x dosing). Efficacy for first responders was higher, OR 0.32, p = 0.01. First responders had a much higher incidence, allowing greater power, and reducing the effect of confounders such as misdiagnosis of other conditions or survey issues.
Performance is similar to placebo for the first 3 weeks. The effect may be greater with a dosage regimen that achieves therapeutic levels faster [tandfonline.com]. ~40% of participants suspected they might have had COVID-19 before the trial, the effect in people without prior COVID-19 may be higher.
Authors note:
- the trial was underpowered
- investigation into more frequent dosing may be warranted
- insufficient dosing with no participants achieving more than the in vitro EC50
Internet survey RCT subject to survey bias. There were no deaths or ICU admissions. Low risk healthcare workers, median age ~40. 494 1x/week dosing, 495 2x/week dosing, 494 control participants (1x and 2x participants received the same overall dosage). COVID PREP. NCT04328467 (history).
risk of hospitalization, 50.1% lower, RR 0.50, p = 1.00, treatment 1 of 989 (0.1%), control 1 of 494 (0.2%), NNT 987.
risk of case, 27.0% lower, HR 0.73, p = 0.12, treatment 58 of 989 (5.9%), control 39 of 494 (7.9%), NNT 49.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Rajasingham et al., 21 Sep 2020, Randomized Controlled Trial, USA, peer-reviewed, 22 authors, trial NCT04328467 (history) (COVID PREP).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Clinical Infectious Diseases MAJOR ARTICLE Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial Radha Rajasingham,1, Ananta S. Bangdiwala,1 Melanie R. Nicol,1 Caleb P. Skipper,1 Katelyn A. Pastick,1, Margaret L. Axelrod,2 Matthew F. Pullen,1 Alanna A. Nascene,1 Darlisha A. Williams,1 Nicole W. Engen,1 Elizabeth C. Okafor,1 Brian I. Rini,2 Ingrid A. Mayer,2 Emily G. McDonald,3 Todd C. Lee,3 Peter Li,4 Lauren J. MacKenzie,5 Justin M. Balko,2 Stephen J. Dunlop,1,6 Katherine H. Hullsiek,1 David R. Boulware,1,a and Sarah M. Lofgren1,a; on behalf of the COVID PREP team (See the Editorial Commentary by Goldman on pages e844–7.) Background. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging virus causing the ongoing coronavirus disease 2019 (COVID-19) pandemic with no known effective prophylaxis. We investigated whether hydroxychloroquine could prevent SARS-CoV-2 in healthcare workers at high risk of exposure. Methods. We conducted a randomized, double-blind, placebo-controlled clinical trial of healthcare workers with ongoing exposure to persons with SARS-CoV-2, including those working in emergency departments, intensive care units, COVID-19 hospital wards, and first responders. Participants across the United States and in the Canadian province of Manitoba were randomized to hydroxychloroquine loading dose then 400 mg once or twice weekly for 12 weeks. The primary endpoint was confirmed or probable COVID-19–compatible illness. We measured hydroxychloroquine whole-blood concentrations. Results. We enrolled 1483 healthcare workers, of whom 79% reported performing aerosol-generating procedures. The incidence of COVID-19 (laboratory-confirmed or symptomatic compatible illness) was 0.27 events/person-year with once-weekly and 0.28 events/person-year with twice-weekly hydroxychloroquine compared with 0.38 events/person-year with placebo. For once-weekly hydroxychloroquine prophylaxis, the hazard ratio was .72 (95% CI, .44–1.16; P = .18) and for twice-weekly was .74 (95% CI, .46–1.19; P = .22) compared with placebo. Median hydroxychloroquine concentrations in whole blood were 98 ng/mL (IQR, 82–120) with onceweekly and 200 ng/mL (IQR, 159–258) with twice-weekly dosing. Hydroxychloroquine concentrations did not differ between participants who developed COVID-19–compatible illness (154 ng/mL) versus participants without COVID-19 (133 ng/mL; P = .08). Conclusions. Pre-exposure prophylaxis with hydroxychloroquine once or twice weekly did not significantly reduce laboratoryconfirmed COVID-19 or COVID-19–compatible illness among healthcare workers. Clinical Trials Registration. NCT04328467. Keywords. COVID-19; hydroxychloroquine; healthcare workers; pre-exposure prophylaxis. Coronavirus disease 2019 (COVID-19) creates a substantial strain on the healthcare system, with frontline healthcare workers at increased risk of infection, and yet they are simultaneously essential for sustaining an adequate emergency response. Unfortunately, at present, no effective oral chemoprophylaxis or vaccination against COVID-19 exists. On 7 October 2020, the Centers for Disease Control and Prevention (CDC) reported over 173 000 cases of COVID-19 among healthcare Received 17 August 2020; editorial decision 10 October 2020; published online 17 October 2020. a D. R. B. and S.M. L. contributed equally to this work. Correspondence: R. Rajasingham, 689 23rd Ave SE,..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit